JAPANESE SOCIETY OF VASCULAR COGNITIVE IMPAIRMENT(2014 No.1)====================================================================================================================================1

JAPANESE SOCIETY OF VASCULAR COGNITIVE IMPAIRMENT(2014 No.1)

ǒ ǩʌʛɨ̪ʷɏȽřÆȿˎM5ƻƷ    

Vas-Cog JapanȮ´˰ ˷˧ƅµ ǒǩbĤWªȵMã˜ğĸGN»ĚM̗ʝM˜ŮYʖ8)Y̜ĆKÈ)ʷɏȽMƚʆǉ.ņþ8!ʷɏ

M.(]U:"ˌ̗̜ȽƚʆMƗȞJņþN!ĈřɁʤļMVJĆɔÆb˕+@ȭÀ\;ɔÆɴȘřʤļ-\YŌ/JĮ̌HJ

ǒǩK(CF!4MǶCF)U:"4Mȭ˃NȿŮ˘¦ĸK,)XF˪ʣJ$ʛɨHʷɏȽM˴Ð%KD)FYġǹKǔǜĳð:^Į̌Hʅ+\_F

F!ƍǪñ̎M[*JĎJ^ʛɨƘʷɏȽ

)U:"4M[*JʷɏȽM­ƒɁȻƚGH)*ʨȠbˌ+@ǌ8)Żƀ)ʦȠ-\(^e~g¢ȼK˴:^ɐɠN!Ɨ

ʍƁɁ¡ŁɑɁɐɠb˜X^4H.ȉX\˚J˜ȁb˝3DD(]!¢ŧÊľʷ_F)U:"

ɏȽZ¢nyȼ˴˛ʷɏȽ!ø̊Û

 4M[*Jǌ8)řʝɁɔÆɁʣʼKƔ̊ľʷɏȽJIMȼƢZȍȾȎYǾ#Kʩ

+F!ʛɨMǽʉɁ¡ĲˋɁ˾şHʷɏȽ

ǖ6_DD(]U:"ȿȽHMȖ)˴˛KD)Fɐɠʩǖ8!ǌ

 ¤Ǎ!˖ŽMȺřɐɠK[CF!̗ʛĺ8)ʰǋȎZǌ8)ȍȾȎM˲ȿKȿŮ6

Z̗ʊʛȽ̞ʊˋȸźȽ̟!ɭūȼJIMȰ<F)14HG!ǒǩbœXH8@»̎èȐʃƣȼN!ʛɨƘʷɏȽKþ+F!eÊMÚZ-J̗̜ĆɔÆMɸƸȿŮKˈ:~g¢ȼM˪ʣJđ˺ĵŖGY(^4^4HbɈǺH8FǩřÆ.ǌ@Kʯɡ6

H.ǖ\-KJ]U8@"6\K̗̜ʆK_U8@"ǩÆNǑK 2010 Ž-\ɐɠÆH,)FNʌʛɨȼŇHe~g¢ȼM

8Fȿˎ8!2014 ŽUGK 5 ĴMɐɠÆbȼȮ.êŗ:^4H.ǝˠɁG6+(^4ɴFŨ8;DȿŮ8Fĕ]U8@"4Mñ

H.ǖ\-K6_!ǌ@JʦȠ-\Mɐɠ˫N½ƌU:U:ȿŮ:^4H.ǦƋ6_.œU]U8@̞§ķ̟"U@ CAA (cerebral

F,]!ɂǹǍMɟǶɁJ5ĕþb,ƋBamyloid angiopathy)Y̗̜ĆKÈCFƗņ88F)U:"
2014 Ž 10 Ǣ 1 ǒF,]!4M@XMʌg¢vpʰǋƯ





 !
"  !








 "
  !



"



 







  "With society ageing, AD increases and becomes more related to vascular abnormality.
2

JAPANESE SOCIETY OF VASCULAR COGNITIVE IMPAIRMENT(2014 No.1)

VAS-COG JAPAN 2014 Ń ĥ¥˪ŌřŌř˹Ĉřɐɠɛ¡ɖɴȼƢìɛřîǩɘĩ VAS-COG JAPAN 2014 NżƦ 26 Ž 8 Ǣ

ȵ.¨ǖɎJ4HY(]!ǡ˖GN VCI H

23 ǒ!º˨̓øMoº˨bÆńK8FąƶɁKĘ]ƭa_^ǽÆYņ+F)

8F˲Ý6_U8@"̥ĴɈb˕+@ȃĝU:"¤Ǎ!e~g¢ȼMT*-\

M­G!½ĴóXFǫºÁŊMļGɐɠÆ

ʤFY!ȿȽKʛɨĵŖM˴©.ƹǄ6_b˲Ý:^˟QKJ]U8@"Æ˰Nº˨^[*KJCF,]!«ȻƚMˏ̂N-JƂɡĈɛŌřɖɴìɛMȈ˫ǅǼǇƼHŧ

]ȩUCF/@[*G:"ȰG!37 ̌M¤ʒȝ̌Kþ+Fȧõˀȝ!

ƵʼȧõˀȝGN Wallin A ãȰ-\ʛɨuvh!Ǉʇˀȝ>M¿HɅ]A1ƘʷɏȽMgk¢l¢KD)F5ˀȝ

6cMìš.(]!ȐȿJ˂ʽGɅ]¦.

Ʃ/U8@"˖Ž!ʷɏȽǔǦʰǋM˪ʣ

]U8@"º˨N˰)ȃĝNYB`cG:

Ƙ.Ę]7@6_F)U:.!ʛɨƘʷɏ

.!“UC@]”Hȑ_^Ǜ˳M­GtgjȽMǡYÔ̋K@^ƹǺN½GYʛȕʌ˴wbǷ8W̐Ĺ.(]U:"ÏŽ!8 ǢMº˱̞BBB̟˾şK[^̖ȕeMȜ˨NȟǟKƜU6_^4H.ŋ)MG:.! ðG(]!ãȰN>MgkeG:"ƆƉǒNž)J4HKŧ̃ȗ9]MǠōGȆ

/ɷ/!ȧõˀȝH8FǒǩʷɏȽřÆȮ˒Ɂˡ58Z:)ōÖKƙU_U8@"´˰MǳįãȰ-\ DIAN,A4 ɐɠJIǡǌ øǒŉ!˿ƿ:^peº˨Me~g¢ȼɐɠKD)F5ɱ¾.

Ggi¢ŌřɬɖɛM Wallin A ãȰ(]U8@"ÏŽKØCFʕƫɐɠʆMĀ-\!MCI K˴:^rpwx

VHJ^[* Young Investigator’s award M¢.(]U8@"23 ǒĊø­N¤ʒĚȝ!

ˤʅ.(]!ǡáɘˊ̢̌T-ŒĀˊ̣̌w{¢ȿʞ.(]!ĊƌMuvh.ˤʅ6_U8@"U@!ƥʧÆGN

GN$ʛɨƘʷɏȽb)-Kʰǋ:^-%

VasCog-J Ȯ´˰M˷˧ƅµǇƼ-\ǫº˲b¢K!ʛɨƘʷɏ˾ş̞VCI̟!Ƀˋ

ÝMĸ˽řÆKD)FǒɞJIMɱ¾.(§ʛɨƘʷɏȽ!˥ÇƘʛɨƘʷɏȽ

]U8@"˴ÐğÉM5ŪüM,ʘGǪŽ

CADASIL, CARASIL MʰǋŁțMɱ¾.

M VasCog world 2015 J\QKĠġ˲ÝHJ(]!ȭȨH>MĮ̌ȠK˴8FȐȿJƟ^ VasCog-J 2015 Kģ2F!Ŝ](^ɐɠÆʤ¹ǂ.(]U8@"ǩɐɠÆMŤ˃H:

KJC@[*KƖ)U:"4Mńb,×]^ʛɨƘʷɏȽNe~g¢ȼHMŅ8FĒ1Əɓȳ8¦3U:"

4

JAPANESE SOCIETY OF VASCULAR COGNITIVE IMPAIRMENT(2014 No.1)

VAS-COG Japan 2014 Đ ˃ʮº˨ƂɡĈɛŌřĈřɐɠɛɖɴìɛřȈ˫ǅǼ ɥ 5 Ĵ VAS-COG Japan 2014 b¥˪ŌřĈ¨ěʩJȽȨbʷɏƒȮřɁʈǞ-\ʅŢřɐɠɛ îǩɘĩǇƼHoº˨

8F̈/̠g¢px¢GNɈ̚

G 2014 Ž 8 Ǣ 23 ǒKêÝ6<F̈/U8ʿ¤ãȰ-\ļŀKĿY_Z:)Ƀˋ§Ƙ@̡4_UGMˡĔ 4 ĴMɐɠÆN);_ʛɨƘʷɏȽMĮ̠̌˝ʜǽʉ˾şMʈǞYǫºGM˲ÝG8@MG̠º˨GM˲Ý

HJ^ʣĵ̠¢uM EBM bbɂ6c-\ǦƋ8F̈/U8@.̠¤D

IM[*Kɒ:-bëÊɁK,ʳ̈/U8ƒ˩.(]U8@̡ǫºKȆSFY 8 ǢM

@̡U@ȧõˀȝH8F Wallin ãȰ-\̖º˨Mʗ8ǟ6NÏŽɊƉJYMG̠Řɩ

ȕ-\V@ʛɨƘʷɏȽMȧƑb,ʳ̈/.ʓ2_Oº˨Mʓ6be¢G/^Y

U8@̡uvhGNʛɨƘʷɏȽM

MM̠8 Ǣ­ǕGNǩƉKɂ6cKǪF̈2

ʰǋŁț!ȧKȭĻĮ̌HJCF)^e

^-H)*ƒ˩G8@̡ž)ÏŽKȆS^~g¢ľʷɏȽHʛɨƘʷɏȽMĠÍH½ŽMº˨MňNZZʗ8ǟ6NU8G̠ 8@ȗĠƘʷɏȽMƭ)KD)Fŋ1MǛ
ǡɲɁK 121 »Mĕþʆ.(]ɅÆKɲa˳bú)F˂ʽbʜ)U8@̡Ġa<F˥

^4H.G/U8@̡ə.º˨ƂɡĈɛŌÇƘʌŧʛɨȼ CADASIL, CARASIL Mʰǋř̠îǩãȰYº˨ŌřðːH)*4HG̠KD)FY˂ʽ8!ĕþʆM¤śMrx

˴ʢMʛɨƘʷɏȽKʐĦbYCF̈)Ftw.Ǝ\_@MGNJ)-HƖ)U:̡

)^ãȰǍKǌ@Kĕþ8F̈2@-HƖĊø­M¤ʒȝ̌ȿʞ,[Qw{¢ȿʞ)U:̡GNʕƫMãȰ-\.̗)ìšMȿ ½ĴNuvhKƽ]¦3@ “ʛɨʞb̈/̠½ƌMřÆH8FȿŮ:^@XƘʷɏȽb)-Kʰǋ:^-”b¢HMŌ/JüHJ^4Hb²ơ8U8@̡

8̠ȽÖř¡ȰĆř¡ȴà¡ʛȑ¡ʌʛȕ ǡƌKńƪbɝ8Fp˴˱JIMʦȠ-\Y*¤ƃʛɨƘʷɏȽ

º˨GN¥˪MǬĽȥK»ȇ.́U]̠ɂ

bʅ+ɉ:4HbƟķ8F,]U8@̡Æ

6cKʑ̛bƬCF̈2@-HƖ)U:̡

ńb 2 ¢Gʜ)U8@MG̠əʎːè½ĴMɐɠÆ.ǪŽǫºG˲Ý²śMFKNĕþG/U<cG8@.̠>_?_VAS-COG world Kģ2F̠ŋ1MɐɠʆMMãȰǍ-\ˆ˪Jˀȝb̈2@HƖ)UĕþbƎF̠U:U:4Mñ˫Mɐɠ.˜:̡ȽÖřṀ-\N|x¢

Ů:^4HM¤ÿKJ_OH̍CF)U:̡

GŵȶÔ°ãȰ-\ʷɏȽƚʆGV\_^

6fe

JAPANESE SOCIETY OF VASCULAR COGNITIVE IMPAIRMENT(2014 No.1)

Vas-COG JAPAN ª ʳ»ÆŃĥŌ˵ŌřŌř˹Ĉřɮɐɠɛ ʍƁ˥ÇŖȍȾř ǳ§ ɢ¤ ǒǩ VAS-COG ɐɠÆ ɥ̦Ĵªʳ»Æ.! ƃ-\ǳįǩÆ̏ĮH­ųÚµãȰ̞º˨
2014 Ž 8 Ǣ 23 ǒ(Ĺ)oº˨̞6 ˼ƂɡĈɛŌřĢʵǇƼ̟!ŞŵŎż̞âȡǩÆ˂ŝ 6̟Kǎ)Fªʳ» 16 Ģ.ĕþ8˲ŌřɬɖɛǇƼ̟.ǀʙ6_@"

Ý6_U8@"˂̌H8FN!
$½ƌM˲Ý

Vas-Cog Asia 4̞APSC2015̟²ś%$řÆĆRģ2FMțÜ%$ŦÄ´ă2015 Ž 10 Ǣ 2 ǒ̞ˬ̟ŬMŔʭ%.ʬ˂6_Á§.ŃĥĖQƮʷ¢ueĸoe¢ŷG˲ÝH

6_U8@"

ȋś&½ƌM˲Ý²ś'&ÆˇKD)F'ɥ 6 ĴřÆ̞2015 Ž̟ ȭʜMŽÆˇ 2,000 íN 2015 Ž 3 Ǣ 31 ǒƉȷȮ´̧ŵȶÔ°ãȰ!ůĚÕżãȰ

UGH8!ġŽ 4 Ǣ 1 ǒÁ˸N 5,000 íKÙ2015 Ž 9 Ǣ 19 ǒ(Ĺ)ǫºd}u¦3:^4H.Ʈʷ6_@"         {h̞Vas-Cog World M˿ÆńG¬ʜ˲Ý̟ &řÆĆRģ2F'
ɥ 7 ĴřÆ̞2016 Ž̟ ǒǩřʝÆ˂ʷśMřÆȳʼMʣÃ̧řƉȷȮ´̧łìȀıãȰ!ůȲȀ¼ãȰʝɐɠģ¦ɈɁ!ɐɠʆʎːK[^Æˇ˟ɥ 8 ĴřÆ̞2017 Ž̟İ!Æĭ 100 »Á¦!ǽ˴ʶȿʜɶɷŽ 1ƉȷȮ´̧ìůɍ¤˦ãȰ!ŧŝ¤ƦãȰĴÁ¦̞̄ŖȿʜĤW!ưˮ́N¨ě̟bɥ 9 ĴřÆ̞2018 Ž̟oe:^ËǵbǩǲĆ8DD!řʝÆ˂ƉȷȮ´̧Ȓ¦åĬãȰ!ǬēƛǤãȰ

ȳʼøGY4_UGMɐɠÆ-\½ƌNřɥ 10 ĴřÆ(2019 Ž)Æbħɜ̞ʎɜNěʉ̟:^4HKJC@"ƉȷȮ´̧ɚ§̀ƇãȰ!ȊȲÌȰãȰřÆĆÑ˜Ŕĭ˰MȒ¦åĬãȰ-\¦ʮ ǬēƛǤãȰ!ɚ§̀ƇãȰ!ȊȲÌȰʣÃMǀ˜KD)Fʹǖ.(C@"ãȰMƉȷªʳ».Ʈʷ6_@̞4_ÁƌÆĭņþ¡ƀŃŔĭ˰MʁȰǘŏãȰ-\N¤»Æ˰öM²ś̟ÆĭȭȨK˯V!ÆĭǉņþHŽÆˇɰç&ĸ˽řÆ'

M,̍).(C@"Vas-Cog World 2015̧řÆʶɻ́Ŕĭ˰MǫȓǭſŏãȰ-\!

Àʞʆ˰Ȳ±ãȰ¡˷˧ƅµãȰœXN e-letter -\řÆʶb˲œ8Fʜ1Ǔ 2015 Ž 9 Ǣ 17-19 ǒ̞ǧ̩Ĺ̟.ʹǖ6_@" ǫºd}u{hG˲Ý˄ăŔĭ˰Mǳ§ɢ¤ãȰ-\!ÆĭņþÆ˂˲ÝɳɽH½ƌMČüKD)Fʹǖ.

MÑ˜HÆˇɰçMÑ˜!¬QKÆʫɆǯ

(C@"ȧõ̏ĮH8F!ǩ̉ŀRM˅ȪMƓʣƘ.ʹǖ6_!Ɇ´KNǬēƛǤã
8

JAPANESE SOCIETY OF VASCULAR COGNITIVE IMPAIRMENT(2014 No.1)

Ȱ.Ʈʷ6_@"U@ˉÿÆĭöƃbË]!

ŧŝ¤Ʀ ǫºŌřŌř˹ Ĉřɮɐɠɛ

˄ăÊˋƈĆK¯]ð:4HKJC@"

ƐȯĲìɛřǇƼŦÄ´ăŬMÃ̧´ăŬ˰Mǳ§ɢ¤ãȰǫȓǭſŏ ƇøŌřŌř˹ Ĉřɐɠɛ-\ʹǖ.(]!®H8FÆĭɨȮHŽÆʌɖɴìɛřˀƄǇƼˇƑėǵăbŽ˳ 583,102 íG´ăŬb£ţů̅ŏ ŲƫĈɛŌř ìɛřˀƄ ɖrɴìɛ¡ʄŽɛñ˫ǇƼ}KŔʭ:^4H.Ʈʷ6_@"ő

ɯN 4 Žbē÷H:^"îǩɘĩ ¥˪ŌřŌř˹ ĈřɮɐɠɛƊĭKD)F̧ȭªʳ»N>MUUèĭȮ

ɖɴȼƢìɛřǇƼ´KɝʜũÄ8!½ƌNğȮ´-\ 3-5 Ģɞ˰Ȳ±ɚȲɌɡʌʛɨɐɠx{¢ ɖƃʱ˂ĭMǀʙb,̍):^4HHJC@" ɴìɛřɐɠ˧˧˰
ʁȰǘŏ ǫºĈɛŌř ̗̜ʰȾɛǇƼ& ƊĭĢɪ'ɗ¸ÒĬ ĈȾȎ»ʔĪÆ -a6/ʮƕ

̏Į

ȼ˹˹˰

ǳį Ō˵ŷɡŌřŌř˹ ĈřɐɠɛłìȀı ƠŕŌřŌř˹Ĉřɮɐɠɛ

ʄŽĈɛřŌˀƄ ʌɖɴɛřǇƼñŖƒʛɨȰȦ¡ʚȮřǇƼȮ´˰ǬēƛǤ ŌñŌřĈř˧ ɖɴìɛřˀ˷˧ƅµ űůŌřŌř˹ ĈŸʚřɹĠƄǇƼɐɠɛ ɖɴìɛǇƼȈ˫ǅǼ º˨ƂɡĈɛŌřŌř˹ ĈřȮ´ɐɠɛ ɖɴìɛřǇƼɚ§̀Ƈ ǫºŌřŌř˹ Ĉřɮɐɠɛ

äůĄƤ ȡǩŌřŌř˹ ȰÊǽʉʚȮþ̜ĈřǇƼ

řǇƼȊȲÌȰ ɿ̒ŌřŌř˹ Ĉřɮɐɠɛ

ǳ§ɢ¤ Ō˵ŌřŌř˹ Ĉřɮɐɠɛ

ʌɖɴìɛřǇƼ

ʍƁ˥ÇŖȍȾřǇƼìůɍ¤˦ ĸ˽ĈȾɗɕŌř ʍƁĈřůĚÕż ųǱŌř Ĉř˧ìɛřˀƄɐɠx{¢ǇƼìɛřɥ¥ǇƼ

Ȓ¦åĬ ̙ĘŌřĈř˧ÓÚřɛ ȰÊ

ůȲȀ¼ ˬȌŌřŌř˹ ʌʄĆ¡ɖɴöƏřǇƼȼƢř̞ɖɴìɛř̟ǇƼ

ŵȶÔ° ɔÆĈȾȎ»˄ĶǌĩÆ éĉÀȼ˹ ɖɴìɛ ˧˰

9JAPANESE SOCIETY OF VASCULAR COGNITIVE IMPAIRMENT(2014 No.1)

VAS-COG Asia Đ ˃ʮĸ˽ĈȾɗɕŌřʍƁĈřɐɠx{¢¡ǇƼůȬȼ˹¡ůȬflx{¢
ʌʛɨx{¢¡x{¢˰ìůɍ¤˦ VAS-COG Asia NeveŎżȏʌċ­řþKDJ.CF)^MGNJ)-HƖ)UÆ̞APSC 2014̟Hêġ˲ÝG 9 Ǣ 12 ǒĊ:"8-Y!ªȵ»ĚM̦úbďX^evƌKĜćMĸ˽Æ˂ńG˲Ý6_U8@"

eGNʷɏȽHʌċ­YȣȿɁKņþ8F

APSC 2012 MÆ˰bǫºGăX@˽K˷˧

)^4H-\!VAS-COG Asia MǮ@:ƊúƅµǇƼ-\M5ʣǥbę2F VAS-COG.½ƌɄ#˪ʣKJCF)14HN˳ˢ)

Asia bêġ˲Ý6<F)@A)@M.ȿɣ

(]U<c"ªȵM}K(^ǒHJ]!APSC HMêġ˲ÝNǙŽ̑șG˲ǩMʷɏȽɐɠʆZ!4M̉ŀK˴ƒM(

Ý6_@ APSC 2013 Kɷ)F½Ĵ.̤ĴɈ^ǌ˜ȇ˭MĈŸZɐɠʆ.ǒǩ-\ŋǉ

HJ]U:"4Mêġ˲ÝNŌŇƦý8F

ĕþ:^4HN VAS-COG Asia Me)^[*KƖa_U:"J=J\O!2012}KŌ/J˅ȪbǮ@:4H.ǦƋ6_ŽMĕþʆNa;- 10 ĢK:0J-C@M

U:"ǪŽN APSC 2015 . 10 Ǣ 2̩4 ǒK.!2013 ŽKN 50 ĢHJ]!½ĴN 100 Ģ¢ueMoe¢G˲Ý6_Á¦MĕþʆGÆń.ȚŹKJ^H)*ë

U:MG!VAS-COG Asia N 10 Ǣ 2 ǒK˲ĠK!Ĵb˪L^5HKĕþʆ.ņ+F)

Ý6_^4HKJ]U:"ȍŚZeoxw^-\G:"«řÆ˳GNřʝp

.[1!z¢ǏʯY>`CF)^4H

MɊ¶¯]ç_MVJ\;!y¢u-\ǒǩ»KYŌŇK»ȇM(^˲ÝļG

pMɊ¶¯]ç_YȐȿKʜa_!

(]!ÆńN·DǗMupeveŎżȏʾĸ˳MɟǶɁJřʝHǊĆ

G:"APSC 2015 H VAS-COG Asia MêÝ

M¹ȑ.ʜa_F)^M.ȧƑG:"½Ĵř Æ K = P 5 ĕ þ 1 A 6 ) "MřÆNĕþʆMŋ6Y6^4HJ.\!
ìšYȼȮ!ȼƢ!Ⱥř!²˶!ȴà!į
ȿ!Ǉʇ!ȽÏǴʬH4_UGÁ¦KŋŰKa@]!ȐȿJˋȹƔɧ.ʜa_!ŌŇ
Ʌ]¦.]U8@"ʷɏȽHʌċ­NÚƅťĨbʋ-:µŌȻƚG(]!ʈǞKʛɨƘđ˺ĵŖbêǣ:^4H.ƀ1ʷˁ6_^[*KJ]!ʌʛɨ˾şHʷɏȽM˴a]K˴ƒ.̗UCF)^4H.ĕþʆMņ
12

JAPANESE SOCIETY OF VASCULAR COGNITIVE IMPAIRMENT(2014 No.1)

VAS-COG Japan 2015 M 5ɱ¾
ŵȶÔ°̞éĉÀȼ˹ɖɴìɛ̟ůĚÕż̞ųǱŌřĈř˧ìɛřˀƄìɛřɥ¥̟ Ǫ@^żƦ 27 Ž̞2015 Ž̟9 Ǣ 19 ǒ̞Ĺ̟Kǫºd}u{hK,)F!ɥ 6Ĵ ǒ ǩ ʌ ʛ ɨ ¡ ʷ ɏ Ƚ ř Æ ̞ VAS-COG
Japan 2015̟b˲Ý6<F)@A/U:"½ĴN VAS-COG World bǒǩKʸʏ:^
4HKƦý8!ġǛ˲ÝH6<F)@A1´HJ]U8@"ĸ˽řÆMǡɲǒKżʜ
8F˲Ý8U:MG!ǚ̆«ǍMřÆRM
ĕþb,̍)8@1ŗ9U:"ĸ˽řÆK
ɀˮ6_@ńĠKN!ĸìřÆRMĕþN

^}owYĘ]¦3˂ʽbʜ)@)H¢K8@)Hʅ+F)U:"ʅ+F)U:" ˖Ž!e~g¢ȼK,2^ʛɨȼ 6FǩřÆN 2010 ŽKɐɠÆH8FȿȮM˪ʣƘb8X:Ńĥ.ņþ8F)U:" ˎ8!ŁɑHʍƁMɐɠʆ.¤ġKÆ8F!
ȺřZđ˺ĵŖṀ-\Y!e~g

ʷɏȽb{¢q}H8FȢ)˂ʽbʜC¢ȼHʛɨƘʷɏȽKNƈ)ê˙Łɇ.(

F/U8@"żƦ 26 ŽƃMªʳ»ÆK,/^4H.ôǖ8DD(]U:"ȧKʌŧʛ

U8F!ɐɠÆ-\řÆRMȿŮbķ]!

ɨȽNegʛɨȽbÀʞH8F!eħɜbɥ 6 Ĵ[]řÆH:^4H.ªʳ»

~g¢ȼHʛɨƘʷɏȽMñȈŴK

ÆGĠƟ6_U8@"ÆĭǉMe}!˄

Éɾ8F)^ȼƢG(]U:"egăÊöMƈĆ!řÆǽ˴ʶMȿʜJI½ƌ

ÂʹKŁE)@e~g¢ȼMǱǩȍoe¢:S/ʺ̌Nŋ1(]U:.!U

ȾʚM˲ȿ.ɬüɁKʜa_F)U:.!

;NřÆ>MYMMȐƘĆ.ƓʣG!ȧK

Y*¤ǍMʛɨȼƢ-\Me¢|Y˪ʕ)ɐɠʆKHCF̘üɁJřÆK˜Ć6

ʣHʅ+\_U:"½ĴMřÆGNe~<^4H.˪ʣG:">M@XKY½ĴM

g¢ȼKŤ:^ʛɨȼƢ-\MeřÆ.ĸ˽řÆHġǛ˲ÝKJC@4H.

¢|b¢H8@Åȴbʅ+F)U:"N;VKJ_OHʅ+F)U:"

U@ʷɏȽʰǋK,2^ȴàƯʝM˪ʣƘ 5ĕ́̈1ŋ1MɂǹǍMȐȿJ5ȿʞ

N˖ŽɄ#ņŌ8F,]!MRI!SPECT!

Z5ʬʽK[]!ǣƟʀJÆHJ^[*țPET MƝŃNʷɏȽMǔǦʰǋ!ȼƢƱǃ!

Üb˜XF)1ƪŗG:"ŋǉMɂǹǍMʚùˤƴɦKŌ/1˅Ȫ8F)U:"ǩř5ĕÆbƒ[],ƋB8F,]U:"ÆGNƵƋˀȝbĤXF!ȴàʰǋK˴:14

JAPANESE SOCIETY OF VASCULAR COGNITIVE IMPAIRMENT(2014 No.1)

VAS-COG H ʷɏȽɐɠMŮǥŌ˵ŷɡŌřŌř˹Ĉřɐɠɛ ʌɖɴɛřǇƼ
VAS-COG ̏Į ǳ į  ŽMǩx¢GN!$8
8 M0b2g¢ȼbŤ˃H:^$  ̞áƘ˥;^ȍȾʚ˲ȿɤ³%Ȟ8Fǌʚ˲ȿÇƘe~g¢ȼȍ̟̕%GÎȱ6_^

Mɱ¾b6<F̈/U8@">Mƌ!TH²śG:"H1K!   NƲ©ǛǦbcIMȍȾʚ˲ȿ.Őǆ8!e~g

ȧśG/^ȠG!̗ɬƃMȍ̕HJ^4H¢ȼMǌʚ˲ȿN!woM̗)´ǵH8.ǦƋ6_F)U:"6\Ke{Fǈˣ6_^[*KJ]U8@">M[*oˋ̨e MÊbŤ˃H

J­G!­ɦƃ-\̗ƃMȽȨGNè1Ă

8@$¢ȍ̕%YǴʬ.ëÊɁK˜c-J-C@yG)^HM4HG:"~H)*æȺƳÊbÎC@  .!ˑƃMƚʆGMǣĂ 4_\MʍƁɐɠN!);_YɞƃMŶƘ.(^!Hȿʞ6_U8@"

4>(_!ǌ8)ȼĵʽKŁE1ǌʚù.

 4MɵǮ-\!4_UGȍȾ¾çǛǦ.

ˤƴ6_F)^4HNƈʻ:^KÙ:^"˞:0@ěʉƘ.˂ʽ6_!½ƌMȍȾʚ

4MJ-K(CF!ŠǐƘe~g¢MʍƁʲ̕NǔǦ-\óǦȄ˼K(^ƚʆ

ȼN!ŇȸbƸDńĠN ̝ȿȽ:^̞Ȕ

K!ńĠK[CFNȿȽø(^)Nø̔Ȩ˗ȫHʪ)U:̟4H-\!¤Ž¤Ž.Ō

ƢMbʟ̕ʆK:^ȑ_KJ]U8@"
 òJǛ˳HJ]U:MG!G/^A2˔˚ ǌ8)ȍ̕H8FM  MǔǦƲJŤï.ǥU_U:" Ž̦ǢKĒȰā

©.ȭĻǴʬ­G(]U:.!4_ÁŊMßɋ-\!ǡǌMʍƁʲ̕H8FǒǩȤH

ȍ̕H8F!ġ9ƳÊbÎȱ8@$  ȍ̕%Y)*S/   ɐɠMʫȴ.ȿʞ6.eg   ˻ƘM  ȂÁ¦MǨȿȽ

_U8@"½ƌ!Ƨ.ĸGY!ǿɫHġ9

ʆRM²˶¾ç.țÜ­M[*G:"yǡǌMʍƁɐɠ.˜ʜ:^4H.ǦƋ6_~ÁŊMȍȾʚÖʠH8F!ksF)U:"ʛɨƘʷɏȽMȍ̕GN!ȰȐ

¢bʷˁ:^o~!øɺɸȨʃƣȼHMʨȠ-\!ɭūȼ!̗ʛĺ!ʊ

egƳÊG(^ ZmˋȸźȽöƏMÓ˺ʚĂǮ.˪ʣJƺƨHJIMƳÊYȍ̕ʚH8Fƺƨ6_[*

J^4H.ʅ+\_^"@A!4_\MÓ

H8F)U:"o~Nčɫr˺ʚMŋ1N!ƌȿīKĘCFÀaCF)eGMġ¤ŇȸbYDŌŠɮbŤ˃H8^Þģ.(]!ʍƁɐɠǀ˜ˈˬMʺ̌K@$  ȍ̕%KÎȱ6_^ƳÊG:"yD)FM˂ʽYƓʣHJ^H²ƞ6_^"~Zm

N!ŠǐƘe~
16

JAPANESE SOCIETY OF VASCULAR COGNITIVE IMPAIRMENT(2014 No.1)

announced a plan for the DIAN-Japan Study as

mellitus, hypertension, and dyslipidemia inthe latest clinical trial. It could be considered

terms of lifestyle-related diseases. However,the Japanese version of DIAN-TTU. In themost of these drugs covered by insurance tend

future, clinical studies in Japan are expected toto be replaced by generic drugs. It is predictedadvance greatly, as in Europe and the Unitedthat the issues related to resources for theStates. In clinical trials for vascular dementia, it

promotion of clinical studies would also need tois important to also confirm the effects of drugs

be discussed.

covered by insurance for the control of diabetesǒ ǩʌʛɨ̪ʷɏȽřÆ(VAS-COG JAPAN)Æ÷
(1) Ģɜ

ÀʞȮ´NȮ´M¶ˤGˤÄ6_̠ÄǦN 2 ǩÆN$ǒǩʌʛɨHʷɏȽřÆǦ 4 ŽH:^̡̞VAS-COG JAPAN̟%Hɜ:^̡(4) ´ǵ

(2) ɈɁ ǩÆNŽ 1 Ĵřʝ́Æb˲Ý:^̡řʝ ǩÆNǒǩK,2^ʛɨƘȼŇHʷɏȽ́ÆNĕþʆMĕþˇG˟İ6_^.̠êHM˴˛KD)FŻƀ)ʦ˫-\ʍƁɁŁÝYěʉG(^̡ɑɁɐɠbʜ)̠Í<Fĸ˽ɁJƉʴñ˫(5) Æˇ̪Æˇ

ɐɠʆHMƝŃ¹ȑb˙9F̠ʷɏȽMē ǩÆN̠ǩÆMˍǓKˉġ:^ÆĭGǸĵZȼƢK,2^ʛɨƘȼŇM˴©bǖ\

Ʀ6_̠ŽÆˇ 2,000 íN 2015 Ž 3 Ǣ 31 ǒ

-K:^4HGûʚMěʉƘYƾ]̠ʷɏ

UGH8!ġŽ 4 Ǣ 1 ǒÁ˸N 5,000 íH:ȽɐɠMǌ8)ñ˫MȿŮKˈ:^@XK^̡ǩÆMÆʫŽƃNȅŽ 4 Ǣ 1 ǒ-\̠

ʯɡ6_@̡

ʂŽ 3 Ǣ 31 ǒH:^̡(3) ǸƦ

(6) ȿˎǦǒ ǩÆNʡǉĢMȮ´,[Qʱ˂ĭK[C ǩÆN 2014 Ž 8 Ǣ 23 ǒKȿˎ8̠ǩÆ

F˟İ6_̠ÀʞȮ´˰H´ăŬbɾ1̡ÛYġǛKǏʜ6_@̡

18

JAPANESE SOCIETY OF VASCULAR COGNITIVE IMPAIRMENT(2014 No.1)

ɻ ́ƌʮƇøŌřɖɴìɛ ǫȓǭſŏ  VAS-COG JAPAN News and Letter Mɥ 1

«̇-\ʩǖ8̠ĸ˽ɁJʥǻG4Mñ˫Ğb,ŭ28U:̡2010 ŽK˲œ6_@ǒ

MȿŮbɈƹ8F)U:̡ǩ News and LetterǩʛɨƘʷɏ˾şɐɠÆNȅŽĕþʆ.ņ

.ǽ˴ʶH8F̠ǩřÆMȿŮK˅Ȫ:^

þ8ȿŮ8F/U8@.̠ǌ@Kǒǩʌʛ4HbǦƋ8F,]U:̡ɻ́ʆH8F̠

ɨ̪ʷɏȽřÆH8Fȿˎ8U8@̡ǩĞG

4MǹJȿŮM,ƫÇ).G/^4HbŌ

N4M˳MɴɼH½ƌMŮǥ̠²śJIbŇäǰKŗ9F,]U:̡řÆÆĭɂǹMǁ˓8U8@̡Common disease H8Fņþ

5ČübI*?,̍)ȳ8¦3U:̡

8F)^ʷɏȽbʛɨƘĵMŁɑHʍƁM

Editors Note
Hirosaki University Mikio Shoji MD., PhD.,
Here, we bring you the first issue of
VAS-COG JAPAN News and Letter.

presented. We aimed basic and clinical studyThisof growing dementia as common disease fromsociety for scientific study of vascular factor of

the aspect of vascular factors to contributedementia stared at 2010, developing withinternal development of this field.

We are

At 4th VAS-COG in

hoping for contribution of this News and Letter

2014, we decided to establish this association asas the official journal of VAS-COG JAPAN. I

official academic society,” VAS-COG JAPAN”.

am very honored to edit this journal. I would

In this issue, background, aim, landscape,like to sincere help by all association members.

growing participants.

schedule, byelaw, and board members are19